$KNTE News
Last published 2y ago
- 2y agoKNTEXOMAXOMAOXOMAPXOMA Corporation Announces Closing of Tender OfferGlobeNewswireEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their
- 2y agoKNTEXOMAXOMAOXOMAPXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.GlobeNewswireEMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered into a merger agreement to acquire Kinnate Biopharma
- 2y agoKNTEKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesPR NewswireKinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS...
- 2y agoKNTEKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesPR NewswireKinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS...
- 2y agoKNTEKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesGlobeNewswireKinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of Kinnate's previously
- 2y agoKNTEFANGHAYNVINEKuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoKNTEKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareGlobeNewswireSAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, today announced it has entered into a
- 2y agoKNTEXOMAXOMAOXOMAPXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightGlobeNewswireEMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ:KNTE) for (i) a base cash price of $2.3352 per
- 3y agoKNTEKinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesGlobeNewswireReported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug
- 3y agoKNTEKinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringGlobeNewswirePromising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application
- 3y agoKNTEKinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesGlobeNewswireReceived FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023Cash, cash equivalents and investments of $204.3 million as
- 3y agoKNTEKinnate Biopharma Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO and SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that the company will participate in two
- 3y agoDAWNKNTEKTTASWTX+1Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029PR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 1, 2023 /PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve
- 3y agoKNTEKinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesGlobeNewswirePresented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting Provided update on ongoing exarafenib monotherapy dose expansion; data-informed
- 3y agoKNTEKinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway GuidanceGlobeNewswireKIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023KIN-8741, a highly selective c-MET inhibitor designed to
- 3y agoKNTEFirst Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant MelanomaGlobeNewswireExarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse eventsBreadth of responses observed across tumor types and BRAF or
- 3y agoKNTEKinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate UpdatesGlobeNewswireAnnounced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research 2023 Annual
- 3y agoKNTEKinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual MeetingGlobeNewswireCompany has initiated enrollment of patients into the monotherapy expansion cohorts Company to host a virtual investor webcast on April 17, 2023, to discuss the AACR results and dose expansion strategy, and to provide
- 3y agoKNTEKinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of ChinaGlobeNewswireKinnate to retain Kinnjiu's cash, intellectual property and other assets, including key personnel and legal entity structureKinnate's cash runway still expected to fund current operations into mid-2024Trial sites open in
- 3y agoKNTEKinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR InhibitorGlobeNewswireSAN FRANCISCO and SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration
- 3y agoKNTEKinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma ConferenceGlobeNewswireSAN FRANCISCO and SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima
- 3y agoKNTEKinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent DirectorGlobeNewswireSAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that its board of directors has appointed a
- 3y agoKNTEKinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers SymposiumGlobeNewswireSAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced the poster presentation of the design and
- 4y agoKNTEKinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate UpdatesGlobeNewswireCash, cash equivalents and investments of $262.1 million as of September 30, 2022; cash runway expected to fund operations into mid-2024 SAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma
- 4y agoKNTEKinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 TrialGlobeNewswireKIN-2787 cleared the predicted efficacious dose at 300 mg bid; dose escalation continues with maximum tolerated dose not yet determined KIN-2787 achieved meaningful exposures that were dose proportional and exceeded
- 4y agoKNTEKinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF InhibitorGlobeNewswireSAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track desig
- 4y agoKNTEKinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland SummitGlobeNewswireSAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in the Piper
- 4y agoKNTEKinnate Biopharma Inc. to Participate in the 2022 Wells Fargo Securities Healthcare ConferenceGlobeNewswireSAN FRANCISCO and SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in a fireside
- 4y agoKNTEKinnate Biopharma Inc. Announces Second Quarter 2022 Financial Results and Recent Corporate UpdatesGlobeNewswirePhase 1 clinical trial for KIN-2787, the company's investigational pan-RAF inhibitor, was initiated in Taiwan by Kinnjiu Biopharma Inc., Kinnate's China joint venture U.S. Food and Drug Administration granted Orphan Drug Designation for KIN-2787 for th
- 4y agoKNTEKinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewswireSAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in the "Bullse
- 4y agoKNTEKinnate Biopharma Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that the company will participate in two upcoming in-person investor conferen
- 4y agoKNTEKinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022GlobeNewswireSAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically
- 4y agoKNTEKinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational UpdatesGlobeNewswireInitial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetini
- 4y agoKNTEKinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248GlobeNewswireSAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomical
- 4y agoKNTEKinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual MeetingGlobeNewswireSAN FRANCISCO and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomical
- 4y agoKNTEKinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational UpdatesGlobeNewswireInitiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the combination portion of KN-8701 to study KIN-2787 wit
- 4y agoKNTEKinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual MeetingGlobeNewswireSAN FRANCISCO and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomical
- 4y agoKNTEKinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies CongressGlobeNewswireFindings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc
- 4y agoKNTEKinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care ConferenceGlobeNewswireSAN FRANCISCO and SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall
- 4y agoKNTEKinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer MeetingGlobeNewswireSAN FRANCISCO and SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall
- 4y agoKNTEKinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall
- 4y agoKNTEKinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers SymposiumGlobeNewswireSAN FRANCISCO and SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall
- 4y agoKNTEKinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248GlobeNewswireSAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall
- 4y agoKNTEKinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 MilestonesGlobeNewswireAnnounces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant melanoma in monotherapy and initiation of a combinatio
- 4y agoKNTEKinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific MeetingsGlobeNewswireAACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors ASCO GI Cancer
- 4y agoKNTEKinnate Biopharma Inc. Announces Addition to NASDAQ Biotechnology IndexGlobeNewswireSAN FRANCISCO and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall
- 5y agoKNTEKinnate Biopharma Inc. Reports Third Quarter 2021 Financial ResultsGlobeNewswireIn collaboration with Guardant Health, announced initial findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study Ended the quarter with cash, cash equivalents and investments of $347.9 million, exclusive of its Ch
- 5y agoKNTEKinnate Biopharma Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO and SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall
- 5y agoKNTEKinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes StudyGlobeNewswireBRAF clinical-genomic landscape research initiative to investigate real-world data from more than 175,000 patients across tumor types, patient demographics and treatment settings Preliminary analyses found that more than half of the patients identi
- 5y agoKNTEKinnate Biopharma Inc. Announces Transition of Chief Scientific OfficerGlobeNewswireSAN FRANCISCO and SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall